Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
921-940 of 3,900 trials

HMB-001 for Glanzmann Thrombasthenia

We are investigating a new treatment to see if it is safe and can help reduce bleeding in people with Glanzmann Thrombasthenia. This study will also look at how the body processes the medication and its effects on quality of life.

Glanzmann's Disease1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematology

Multiple Myeloma: BMS-986453 Treatment

We are testing a new drug for individuals with relapsed or refractory multiple myeloma. The goal is to understand its safety and how it may help manage their condition.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)HematologyOncology

Small Cell Lung Cancer: BI 764532 with Chemotherapy

We are testing how well different doses of BI 764532 are tolerated by people with small cell lung cancer when combined with chemotherapy. This study aims to find the safest and most effective dose.

Extensive Stage Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Advanced Small Cell Lung Cancer: BI 764532 Study

We are testing how well different doses of a new medication work with standard care for people with advanced small cell lung cancer. This study aims to see how well patients tolerate the treatment.

Extensive-Stage Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Nebulized Fentanyl: Facial vs. Intranasal Delivery

We are comparing two ways to deliver nebulized fentanyl to healthy volunteers. This study aims to understand which method may be more effective for future use.

Healthy Volunteers1-2 yearsSafety phase (I)Internal MedicineOtolaryngologyPsychiatryPulmonology

Juvenile Psoriatic Arthritis: Risankizumab Study

We are studying a new treatment called risankizumab for children aged 5 to 17 with active juvenile psoriatic arthritis. The goal is to see if it is safe and effective compared to an existing medication.

Juvenile Psoriatic Arthritis>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyPediatricsRheumatology

DIPG Treatment Study: ONC201 vs. Everolimus

We are testing a new drug, ONC201, for children with newly diagnosed DIPG and related tumors. The goal is to see if it helps improve survival and progression-free time compared to standard treatment.

Brain Stem Glioma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncologyPediatrics

Myotonic Dystrophy Type 1: VX-670 Study

We are testing the safety and tolerability of a new drug, VX-670, in adults with myotonic dystrophy type 1. This study aims to understand how the drug works in the body and its potential benefits.

Myotonic DystrophySafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Hypertonic Lactate After Cardiac Arrest: The LATTE Trial

We are studying whether hypertonic sodium lactate can help reduce brain injury in comatose survivors of cardiac arrest. This trial will also look at its effects on recovery and safety.

Cardiac ArrestComaPost Cardiac Arrest Syndrome≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyNeurology

Follicular Lymphoma: Mosunetuzumab and Zanubrutinib Study

We are investigating a combination of two medications for patients with relapsed or refractory follicular lymphoma. The goal is to see if this treatment improves outcomes and safety compared to existing options.

Follicular Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematology

Ketamine for Depression and Alcohol Use Disorder

We are studying whether ketamine can help adults with depression and alcohol use disorder during their addiction treatment. The trial will also look at the safety of this treatment approach.

DepressionAlcohol Use Disorder6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemotePsychiatry

Pain Management: Dexmedetomidine for Nerve Block

We are exploring the best dose of dexmedetomidine to enhance pain relief during a nerve block procedure. This study will also check for side effects and benefits like reduced opioid use and better patient satisfaction.

Patients Scheduled for Shoulder Operations1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurologyOrthopedics and TraumatologyOtolaryngology

EPO-TRAUMA: Epoetin Alfa for Critically Ill Trauma Patients

We are studying whether epoetin alfa can lower the risk of death and severe disability in critically ill patients after trauma. This trial compares its effects to a placebo treatment.

Traumatic Injury3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Achondroplasia: TransCon CNP Treatment for Infants

We are investigating the safety and growth effects of weekly injections of TransCon CNP in infants with achondroplasia. This study aims to understand how the treatment may help with growth and development.

Achondroplasia1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementEndocrinologyPediatrics

Gastric Cancer: Dostarlimab Immunotherapy Study

We are exploring a new treatment approach for patients with localized gastric cancer to see if delaying surgery while using Dostarlimab can be effective. The study aims to evaluate patient responses and safety over time.

Metastatic Gastric Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyOncology

Weight Management in Schizophrenia: Semaglutide Study

We are investigating whether semaglutide can help patients with schizophrenia and obesity improve their weight and metabolic health. This study compares semaglutide to a placebo to see its effects on various health measures.

Metabolic Control in Antipsychotic-Using Patients6-12 monthsConfirmation phase (III)>20 visitsInvestigational MedicinesEndocrinologyPsychiatry

Colorectal Cancer: Reduced Dose Chemotherapy for Older Patients

We are studying whether a lower dose of chemotherapy is as effective as the standard dose for older patients with advanced colorectal cancer. This may help improve quality of life and reduce severe side effects.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Cerebral Amyloid Angiopathy: New Treatment Approaches

We are studying whether non-invasive vagus nerve stimulation and low-sodium oxybate can help clear amyloid-beta from the brain in patients with cerebral amyloid angiopathy. This research aims to improve understanding of potential treatments for this condition.

Cerebral Amyloid Angiopathy≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Achondroplasia: Infigratinib for Children

We are investigating a new medication, infigratinib, for children aged 3 to under 18 with achondroplasia. The study aims to see if it helps improve growth and body proportions while ensuring safety.

Achondroplasia>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesOrthopedics and TraumatologyPediatrics

Juvenile Idiopathic Arthritis: Baricitinib Study

We are investigating whether the medication baricitinib is safe and effective for children and teens aged 1 to 17 with juvenile idiopathic arthritis. This study aims to improve treatment options for this condition.

Juvenile Idiopathic Arthritis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology